Mekinist(trametinib)
Mekinist (trametinib) is a small molecule pharmaceutical. Trametinib was first approved as Mekinist on 2013-05-29. It is used to treat melanoma and non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 2 and dual specificity mitogen-activated protein kinase kinase 1. In addition, it is known to target serine/threonine-protein kinase B-raf.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Trade Name
FDA
EMA
Mekinist
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mekinist | New Drug Application | 2020-06-23 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TRAMETINIB DIMETHYL SULFOXIDE, MEKINIST, NOVARTIS | |||
| 2030-03-16 | ODE-428 | ||
| 2026-03-16 | I-908, NP | ||
| 2025-12-22 | PED | ||
| 2025-11-04 | PED | ||
| 2025-10-30 | PED | ||
| 2025-06-22 | I-895 | ||
| 2025-05-04 | ODE-183 | ||
| 2025-04-30 | ODE-182 | ||
| 2024-12-22 | PED | ||
| 2024-06-22 | ODE-148 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Trametinib Dimethyl Sulfoxide, Mekinist, Novartis | |||
| 10869869 | 2033-08-30 | U-3184 | |
| 8580304 | 2032-01-28 | DP | |
| 9155706 | 2032-01-28 | DP | |
| 9271941 | 2032-01-28 | DP | |
| 9399021 | 2032-01-28 | DP | |
| 8703781 | 2030-10-15 | DS, DP | U-1712, U-2020, U-2037, U-2302, U-2305, U-3564 |
| 8952018 | 2030-10-15 | U-2020 | |
| 7378423 | 2027-05-29 | DS, DP | |
| 8835443 | 2025-06-10 | U-1581, U-1582, U-2020, U-2037, U-2302, U-2305, U-3564 | |
HCPCS
No data
Clinical
Clinical Trials
237 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | 28 | 38 | 7 | 1 | 12 | 73 | ||
| Neoplasms | D009369 | C80 | 38 | 26 | — | 1 | 1 | 57 | |
| Non-small-cell lung carcinoma | D002289 | 15 | 12 | — | 1 | — | 21 | ||
| Neurofibromatosis 1 | D009456 | Q85.01 | 1 | 3 | — | 1 | — | 4 | |
| Glioblastoma | D005909 | EFO_0000515 | 1 | 2 | — | 1 | — | 4 | |
| Astrocytoma | D001254 | EFO_0000271 | 1 | 2 | — | 1 | — | 4 | |
| Oligodendroglioma | D009837 | EFO_0000631 | 1 | 1 | — | 1 | — | 3 | |
| Ganglioneuroma | D005729 | — | 1 | — | 1 | — | 2 | ||
| Ganglioglioma | D018303 | — | 1 | — | 1 | — | 2 | ||
| Multiple hamartoma syndrome | D006223 | E71.440 | — | 1 | — | 1 | — | 2 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thyroid neoplasms | D013964 | EFO_0003841 | 2 | 9 | 1 | — | — | 11 | |
| Sarcoma | D012509 | 1 | — | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 10 | 10 | — | — | — | 15 | ||
| Multiple myeloma | D009101 | C90.0 | 3 | 8 | — | — | — | 10 | |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 4 | 4 | — | — | — | 8 |
| Myeloid leukemia acute | D015470 | C92.0 | 3 | 2 | — | — | — | 5 | |
| Prostatic neoplasms | D011471 | C61 | 1 | 3 | — | — | 1 | 5 | |
| Lung neoplasms | D008175 | C34.90 | 3 | 4 | — | — | — | 5 | |
| Lymphoma | D008223 | C85.9 | — | 5 | — | — | — | 5 | |
| Glioma | D005910 | EFO_0000520 | 2 | 3 | — | — | — | 5 | |
| Anaplastic thyroid carcinoma | D065646 | 2 | 3 | — | — | — | 5 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 2 | — | — | — | 4 |
Show 45 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cancer pain | D000072716 | G89.3 | 2 | — | — | — | — | 2 | |
| Hematologic neoplasms | D019337 | 1 | — | — | — | — | 1 | ||
| Castration-resistant prostatic neoplasms | D064129 | 1 | — | — | — | — | 1 | ||
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | — | — | — | — | 1 | |
| Primary myelofibrosis | D055728 | D47.4 | 1 | — | — | — | — | 1 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | — | — | — | — | 1 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | — | — | — | — | 1 | |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | — | 1 |
| Hodgkin disease | D006689 | C81 | 1 | — | — | — | — | 1 | |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | C92.2 | 1 | — | — | — | — | 1 |
Show 20 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TRAMETINIB |
| INN | trametinib |
| Description | Trametinib is a pyridopyrimidine that is used (as its dimethyl sulfoxide addition compound) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, an antineoplastic agent, an anticoronaviral agent and a geroprotector. It is a pyridopyrimidine, an organofluorine compound, an organoiodine compound, a member of acetamides, a ring assembly, a member of cyclopropanes and an aromatic amine. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; MEK (MAPK kinase) inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1 |
Identifiers
| PDB | 7M0Y |
| CAS-ID | 871700-17-3 |
| RxCUI | 1425099 |
| ChEMBL ID | CHEMBL2103875 |
| ChEBI ID | 75998 |
| PubChem CID | 11707110 |
| DrugBank | DB08911 |
| UNII ID | 33E86K87QN (ChemIDplus, GSRS) |
Target
Agency Approved
MAP2K2
MAP2K2
MAP2K1
MAP2K1
Organism
Homo sapiens
Gene name
MAP2K2
Gene synonyms
MEK2, MKK2, PRKMK2
NCBI Gene ID
Protein name
dual specificity mitogen-activated protein kinase kinase 2
Protein synonyms
ERK activator kinase 2, MAP kinase kinase 2, MAPK/ERK kinase 2, MEK 2, mitogen-activated protein kinase kinase 2, p45
Uniprot ID
Mouse ortholog
Map2k2 (26396)
dual specificity mitogen-activated protein kinase kinase 2 (Q9D7B0)
Alternate
BRAF
BRAF
Organism
Homo sapiens
Gene name
BRAF
Gene synonyms
BRAF1, RAFB1
NCBI Gene ID
Protein name
serine/threonine-protein kinase B-raf
Protein synonyms
94 kDa B-raf protein, B-Raf proto-oncogene serine/threonine-protein kinase (p94), B-Raf serine/threonine-protein, murine sarcoma viral (v-raf) oncogene homolog B1, p94, Proto-oncogene B-Raf, v-raf murine sarcoma viral oncogene homolog B, v-Raf murine sarcoma viral oncogene homolog B1
Uniprot ID
Mouse ortholog
Braf (109880)
serine/threonine-protein kinase B-raf (P28028)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,159 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,514 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more